Investigation of the Molecular Interactions Regulating the Function of Human Cardiac Myosin
Sign Up to like & getrecommendations! Published in 2017 at "Biophysical Journal"
DOI: 10.1016/j.bpj.2016.11.1408
Abstract: Cardiac myosin interacts cyclically with actin in the presence of ATP in the sarcomere to drive heart contraction. Previous fiber studies suggested that the structure and function of myosin in the thick filaments are regulated… read more here.
Keywords: hep hmm; myosin; cardiac myosin; human cardiac ... See more keywords
Impact of Para-Nitroblebbistatin on Human Beta-Cardiac Myosin at the Molecular and Tissue Levels
Sign Up to like & getrecommendations! Published in 2017 at "Biophysical Journal"
DOI: 10.1016/j.bpj.2016.11.668
Abstract: Inherited cardiomyopathies are a common form of heart disease caused by mutations in sarcomeric proteins with beta cardiac myosin being one of the most frequently affected genes. Since the discovery of the first cardiomyopathy associated… read more here.
Keywords: beta cardiac; myosin; cardiac myosin; para nitroblebbistatin ... See more keywords
Modulation of Cardiac Myosin by a Small Molecule Agent that Targets the Regulatory Light Chain
Sign Up to like & getrecommendations! Published in 2017 at "Biophysical Journal"
DOI: 10.1016/j.bpj.2016.11.669
Abstract: A small molecule modulator of cardiac myosin enzymatic function has been identified (refered to as compound-A) and our characterization demonstrates that this agent exerts its effect through the regulatory light chain (RLC) of myosin. Compound… read more here.
Keywords: myosin; small molecule; light chain; regulatory light ... See more keywords
Nanomechanical Phenotypes in Hypertrophic Cardiomyopathy caused by Missense Mutations in Cardiac Myosin-Binding Protein C
Sign Up to like & getrecommendations! Published in 2017 at "Biophysical Journal"
DOI: 10.1016/j.bpj.2016.11.907
Abstract: We investigate the molecular mechanisms that induce hypertrophic cardiomyopathy (HCM) in the 10-20% of patients who carry missense mutations in MYBPC3, the gene coding for cardiac myosin-binding protein C (cMyBP-C). Our starting point is the… read more here.
Keywords: protein; myosin binding; hypertrophic cardiomyopathy; missense mutations ... See more keywords
The Effect of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Right Ventricular Structure and Function in Chronic Systolic Heart Failure (cosmic-hf)
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Cardiac Failure"
DOI: 10.1016/j.cardfail.2020.09.017
Abstract: Background Omecamtiv mecarbil (OM) is a cardiac myotrope which selectively activates cardiac myosin and thereby increases cardiac contractility. The aim of the current study was to determine the effect of therapy with OM on right… read more here.
Keywords: omecamtiv mecarbil; right ventricular; cardiac myosin; failure ... See more keywords
Point mutations in the tri-helix bundle of the M-domain of cardiac myosin binding protein-C influence systolic duration and delay cardiac relaxation.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of molecular and cellular cardiology"
DOI: 10.1016/j.yjmcc.2018.05.001
Abstract: Cardiac myosin binding protein-C (cMyBP-C) is an essential regulatory protein required for proper systolic contraction and diastolic relaxation. We previously showed that N'-terminal domains of cMyBP-C stimulate contraction by binding to actin and activating the… read more here.
Keywords: myosin binding; relaxation; binding protein; binding actin ... See more keywords
Variable cardiac myosin binding protein-C expression in the myofilaments due to MYBPC3 mutations in hypertrophic cardiomyopathy.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of molecular and cellular cardiology"
DOI: 10.1016/j.yjmcc.2018.08.023
Abstract: BACKGROUND Mutations in MYBPC3 are the most common cause of hypertrophic cardiomyopathy (HCM). These mutations produce dysfunctional protein that is quickly degraded and not incorporated in the myofilaments. Most patients are heterozygous and allelic expression… read more here.
Keywords: protein; hypertrophic cardiomyopathy; expression; cell ... See more keywords
Biophysical properties of human β-cardiac myosin with converter mutations that cause hypertrophic cardiomyopathy
Sign Up to like & getrecommendations! Published in 2017 at "Science Advances"
DOI: 10.1126/sciadv.1601959
Abstract: Converter HCM mutations cause only small changes in the biophysics of myosin, suggesting an alternative mechanism for hypercontractility. Hypertrophic cardiomyopathy (HCM) affects 1 in 500 individuals and is an important cause of arrhythmias and heart… read more here.
Keywords: myosin; hypertrophic cardiomyopathy; mutations cause; human cardiac ... See more keywords
Abstract 332: Pharmacologic Characterization of the Cardiac Myosin Inhibitor, CK-3773274: A Potential Therapeutic Approach for Hypertrophic Cardiomyopathy
Sign Up to like & getrecommendations! Published in 2019 at "Circulation Research"
DOI: 10.1161/res.125.suppl_1.332
Abstract: Hypercontractility of the cardiac sarcomere appears to underlie pathological hypertrophy and fibrosis in select genetic hypertrophic cardiomyopathies. Here, we characterize the small molecule, CK-3773274, as a novel cardiac myosin inhibitor that decreases contractility in vitro… read more here.
Keywords: myosin inhibitor; vehicle; myosin; cardiac myosin ... See more keywords
Effects of the cardiac myosin activator Omecamtiv-mecarbil on severe chronic aortic regurgitation in Wistar rats
Sign Up to like & getrecommendations! Published in 2018 at "BMC Cardiovascular Disorders"
DOI: 10.1186/s12872-018-0831-3
Abstract: BackgroundAortic regurgitation (AR) is a valvular disease that can lead to systolic heart failure. Treatment options besides cardiac surgery are limited and consequently severe AR is associated with higher mortality and morbidity when not operated.… read more here.
Keywords: activator omecamtiv; omecamtiv mecarbil; myosin activator; cardiac myosin ... See more keywords
Changes in serum cardiac myosin light chain 1 levels in children with fulminant myocarditis during continuous blood purification.
Sign Up to like & getrecommendations! Published in 2017 at "Revista da Associacao Medica Brasileira"
DOI: 10.1590/1806-9282.63.10.904
Abstract: OBJECTIVE To investigate the changes in serum cardiac myosin light chain 1 (CMLC-1) levels in children with fulminant myocarditis (FM) during continuous blood purification (CBP), as well as to analyze its correlation with other laboratory… read more here.
Keywords: myosin light; changes serum; light chain; levels children ... See more keywords